论文部分内容阅读
背景与目的:基质金属蛋白酶(matrixmetalloproteinases,MMPs)通过降解细胞外基质在肿瘤的侵袭与转移中起着重要作用,MMPs活性又受到其抑制剂(tissueinhibitorofmatrixmetalloproteinase,TIMPs)的调节。本研究通过检测MMP-9、MMP-2、MMP-7及TIMP-1、TIMP-2、TIMP-3mRNA在卵巢肿瘤组织中的表达,探讨其与卵巢癌临床病理特征和预后的关系。方法:应用RT-PCR方法检测48例卵巢癌、21例良性肿瘤及22例正常卵巢组织中MMP-9、MMP-2、MMP-7及TIMP-1、TIMP-2、TIMP-3mRNA的表达。结果:MMP-9阳性率和MMP-9、MMP-2半定量值在卵巢癌组织中明显高于正常卵巢组织(P<0.05)。TIMP-2、MMP-7、TIMP-3在卵巢恶性及良性肿瘤组织中的阳性率及半定量值明显高于正常卵巢组织。MMP-9/TIMP-1在卵巢癌组织中的比值(0.91±0.67)明显高于正常卵巢组织(0.15±0.34)。MMP-9表达水平与卵巢癌的手术病理分期及预后有关,在Ⅲ～Ⅳ期患者中的表达(1.13±0.66)显著高于Ⅰ～Ⅱ期患者(0.60±0.54)(P<0.05);MMP-9其阳性患者平均生存时间为(43.00±17.12)个月,累积生存率为47.37%,明显低于MMP-9阴性者(100%)。结论:MMP-9、MMP-2、MMP-7、TIMP-2、TIMP-3基因在卵巢恶性肿瘤组织中的表达增加。MMP-9的高表达及MMP-9与TIMP-1的平衡失调在晚期卵巢癌的发
BACKGROUND & OBJECTIVE: Matrix metalloproteinases (MMPs) play an important role in tumor invasion and metastasis by degrading extracellular matrix, and MMPs activity is regulated by tissue inhibitors of matrix metalloproteinases (TIMPs). In this study, the expression of MMP-9, MMP-2, MMP-7, TIMP-1, TIMP-2 and TIMP-3 mRNA in ovarian tumor tissues was detected to explore their relationship with clinicopathological characteristics and prognosis of ovarian cancer. Methods: The expressions of MMP-9, MMP-2, MMP-7, TIMP-1, TIMP-2 and TIMP-3 in 48 cases of ovarian cancer, 21 cases of benign tumor and 22 cases of normal ovarian tissue were detected by RT- Results: The positive rate of MMP-9 and the semi-quantitative value of MMP-9 and MMP-2 in ovarian cancer tissues were significantly higher than those in normal ovarian tissues (P <0.05). The positive rates and semi-quantitative values of TIMP-2, MMP-7 and TIMP-3 in ovarian malignant and benign tumor tissues were significantly higher than those in normal ovarian tissues. The ratio of MMP-9 / TIMP-1 in ovarian cancer tissues (0.91 ± 0.67) was significantly higher than that in normal ovarian tissues (0.15 ± 0.34). The expression of MMP-9 was correlated with the pathological stage and prognosis of ovarian cancer. The expression of MMP-9 in stage Ⅲ ~ Ⅳ was significantly higher than that in stage Ⅰ ~ Ⅱ (1.60 ± 0.54, P <0.05) -9, the mean survival time of positive patients was (43.00 ± 17.12) months, the cumulative survival rate was 47.37%, which was significantly lower than that of MMP-9 negative patients (100%). Conclusion: The expression of MMP-9, MMP-2, MMP-7, TIMP-2 and TIMP-3 in ovarian cancer tissues increased. The high expression of MMP-9 and the imbalance of MMP-9 and TIMP-1 in the development of advanced ovarian cancer